GlaxoSmithKline plc Cash Flow Conversion Efficiency
GlaxoSmithKline plc cash flow conversion efficiency. Based on the latest financial reports, GlaxoSmithKline plc (GSKN) has a cash flow conversion efficiency ratio of 0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.22 Billion ≈ $127.88 Million USD) by net assets (MX$15.75 Billion ≈ $906.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GlaxoSmithKline plc (2013–2024)
Cash flow conversion efficiency of GlaxoSmithKline plc from 2013 to 2024. This chart illustrates how GlaxoSmithKline plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest GlaxoSmithKline plc stock price today for real-time trading data and today's change.
GlaxoSmithKline plc Cash Flow Conversion Ratio Explained
GlaxoSmithKline plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GlaxoSmithKline plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline plc ranked by their cash flow conversion efficiency. Also see market value of GlaxoSmithKline plc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DBS GROUP ADR/4 SD 1
F:DEV
|
N/A |
|
Rio Tinto Group
F:RIOA
|
0.042x |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
0.073x |
|
GlaxoSmithKline PLC ADR
NYSE:GSK
|
0.149x |
|
Medtronic PLC
NYSE:MDT
|
0.051x |
|
China Life Insurance Co Ltd A
SHG:601628
|
0.194x |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
0.217x |
|
Accenture plc
NYSE:ACN
|
0.115x |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline plc (2013–2024)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline plc from 2013 to 2024. Review GlaxoSmithKline plc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | MX$13.09 Billion ≈ $753.10 Million |
MX$6.55 Billion ≈ $377.18 Million |
0.501x | +17.00% |
| 2023-12-31 | MX$12.79 Billion ≈ $736.36 Million |
MX$5.48 Billion ≈ $315.20 Million |
0.428x | -41.62% |
| 2022-12-31 | MX$10.10 Billion ≈ $581.03 Million |
MX$7.40 Billion ≈ $426.04 Million |
0.733x | +96.80% |
| 2021-12-31 | MX$21.34 Billion ≈ $1.23 Billion |
MX$7.95 Billion ≈ $457.64 Million |
0.373x | -8.15% |
| 2020-12-31 | MX$20.81 Billion ≈ $1.20 Billion |
MX$8.44 Billion ≈ $485.78 Million |
0.406x | -7.15% |
| 2019-12-31 | MX$18.36 Billion ≈ $1.06 Billion |
MX$8.02 Billion ≈ $461.55 Million |
0.437x | -80.95% |
| 2018-12-31 | MX$3.67 Billion ≈ $211.32 Million |
MX$8.42 Billion ≈ $484.63 Million |
2.293x | +15.66% |
| 2017-12-31 | MX$3.49 Billion ≈ $200.79 Million |
MX$6.92 Billion ≈ $398.13 Million |
1.983x | +51.46% |
| 2016-12-31 | MX$4.96 Billion ≈ $285.62 Million |
MX$6.50 Billion ≈ $373.90 Million |
1.309x | +352.40% |
| 2015-12-31 | MX$8.88 Billion ≈ $510.93 Million |
MX$2.57 Billion ≈ $147.85 Million |
0.289x | -72.41% |
| 2014-12-31 | MX$4.94 Billion ≈ $284.07 Million |
MX$5.18 Billion ≈ $297.88 Million |
1.049x | +13.43% |
| 2013-12-31 | MX$7.81 Billion ≈ $449.58 Million |
MX$7.22 Billion ≈ $415.63 Million |
0.924x | -- |
About GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more